Nancy M. Hardy

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

Aaron P. Rapoport, Edward A. Stadtmauer, Gwendolyn Binder-Scholl et al. · Nature Medicine · 2015 · 832 citations · Full text

Cancer Immunosurveillance, Immunology, Tumor Immunity +9

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

James N. Kochenderfer, Mark E. Dudley, Robert O. Carpenter et al. · Blood · 2013 · 586 citations · Full text

National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide

Bronwen E. Shaw, Antonio Martin Jimenez-Jimenez, Linda J. Burns et al. · Journal of Clinical Oncology · 2021 · 198 citations · Full text

Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation

Marcos de Lima, David L. Porter, Minoo Battiwalla et al. · Biology of Blood and Marrow Transplantation · 2013 · 139 citations · Full text

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

David Porter, Edwin P. Alyea, Joseph H. Antin et al. · Biology of Blood and Marrow Transplantation · 2010 · 138 citations · Full text